These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 6854139)
21. Biliary secretion of sulindac and metabolites in man. Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513 [TBL] [Abstract][Full Text] [Related]
22. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism. Lin JH; Yeh KC; Duggan DE Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111 [TBL] [Abstract][Full Text] [Related]
23. Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation. Kanfer I; Brown C; Konings M; Swarbrick J Biopharm Drug Dispos; 1996 Apr; 17(3):209-21. PubMed ID: 8983396 [TBL] [Abstract][Full Text] [Related]
24. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone. Kitamura S; Tatsumi K Jpn J Pharmacol; 1982 Oct; 32(5):833-8. PubMed ID: 7176218 [TBL] [Abstract][Full Text] [Related]
25. Medical use of dimethyl sulfoxide (DMSO). Swanson BN Rev Clin Basic Pharm; 1985; 5(1-2):1-33. PubMed ID: 3916302 [TBL] [Abstract][Full Text] [Related]
30. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics. Kapetanovic IM; Krishnaraj R; Martin-Jimenez T; Yuan L; van Breemen RB; Lyubimov A Chem Biol Interact; 2006 Dec; 164(1-2):68-75. PubMed ID: 17027946 [TBL] [Abstract][Full Text] [Related]
31. Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism. Davis PJ; Guenthner LE Xenobiotica; 1985 Oct; 15(10):845-57. PubMed ID: 4072250 [TBL] [Abstract][Full Text] [Related]
32. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Strong HA; Renwick AG; George CF; Liu YF; Hill MJ Xenobiotica; 1987 Jun; 17(6):685-96. PubMed ID: 3630204 [TBL] [Abstract][Full Text] [Related]
33. A kinetic study of sulindac in the elderly. Bayley N; Warne RW; Moulds RF; Bury RW Aust N Z J Med; 1987 Feb; 17(1):39-42. PubMed ID: 3476045 [TBL] [Abstract][Full Text] [Related]
34. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825 [TBL] [Abstract][Full Text] [Related]
35. Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL-6-induced differentiation of SKW6-CL4 into IgM-secreting plasma cells. Teraoka H; Mikoshiba M; Takase K; Yamamoto K; Tsukada K Exp Cell Res; 1996 Jan; 222(1):218-24. PubMed ID: 8549666 [TBL] [Abstract][Full Text] [Related]
36. Individual variability in concentrations of urinary sulindac sulfide. Brandli DW; Sarkissian E; Ng SC; Paulus HE Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108 [TBL] [Abstract][Full Text] [Related]
37. The disposition of sulindac. Duggan DE; Hare LE; Ditzler CA; Lei BW; Kwan KC Clin Pharmacol Ther; 1977 Mar; 21(3):326-35. PubMed ID: 300048 [TBL] [Abstract][Full Text] [Related]
38. Placental transfer of sulindac and its active sulfide metabolite in humans. Kramer WB; Saade G; Ou CN; Rognerud C; Dorman K; Mayes M; Moise KJ Am J Obstet Gynecol; 1995 Mar; 172(3):886-90. PubMed ID: 7892880 [TBL] [Abstract][Full Text] [Related]
39. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion. Lin JH; Yeh KC; Duggan DE Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112 [TBL] [Abstract][Full Text] [Related]